Dysregulated TIE-2 expression is associated with blood-brain barrier leakiness and Alzheimer's disease-related neuropathology.

Saved in:
Bibliographic Details
Title: Dysregulated TIE-2 expression is associated with blood-brain barrier leakiness and Alzheimer's disease-related neuropathology.
Authors: Ince S; Cerebrovascular & Dementia Research Group, Learning and Research Building, Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, UK., Van Hulle C; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA., Kollmorgen G; Roche Diagnostics GmbH, Penzberg, Germany., Quijano-Rubio C; Roche Diagnostics International Ltd, Rotkreuz, Switzerland., Gleason C; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, Wisconsin, USA., Bendlin BB; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, Wisconsin, USA., Okonkwo O; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, Wisconsin, USA., Asthana S; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, Wisconsin, USA., Blennow K; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK., Zetterberg H; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.; Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.; Centre for Brain Research, Indian Institute of Science, Bangalore, India., Johnson SC; Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, USA.; Wisconsin Alzheimer's Institute, University of Wisconsin, Madison, Wisconsin, USA., Love S; Cerebrovascular & Dementia Research Group, Learning and Research Building, Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, UK., Miners JS; Cerebrovascular & Dementia Research Group, Learning and Research Building, Bristol Medical School, Translational Health Sciences, University of Bristol, Bristol, UK.
Source: Brain pathology (Zurich, Switzerland) [Brain Pathol] 2026 Jun 07, pp. e70109. Date of Electronic Publication: 2026 Jun 07.
Publication Type: Journal Article
Journal Info: Publisher: International Society of Neuropathology Country of Publication: Switzerland NLM ID: 9216781 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-3639 (Electronic) Linking ISSN: 10156305 NLM ISO Abbreviation: Brain Pathol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1750-3639
DOI:10.1111/bpa.70109